Seqens Seqens

X
[{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Completes Acquisition of Brands from Anglo-French","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Nicotinamide

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The acquisition will strengthen Lupin’s business by adding a portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical company in India.

            Lead Product(s): Nicotinamide

            Therapeutic Area: Nutrition and Weight Loss Product Name: Beplex Forte

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lupin Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY